DE102016123893A1 - T-Zellrezeptoren mit verbesserter Bindung - Google Patents

T-Zellrezeptoren mit verbesserter Bindung Download PDF

Info

Publication number
DE102016123893A1
DE102016123893A1 DE102016123893.7A DE102016123893A DE102016123893A1 DE 102016123893 A1 DE102016123893 A1 DE 102016123893A1 DE 102016123893 A DE102016123893 A DE 102016123893A DE 102016123893 A1 DE102016123893 A1 DE 102016123893A1
Authority
DE
Germany
Prior art keywords
tcr
chain
modified
cell receptor
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE102016123893.7A
Other languages
German (de)
English (en)
Inventor
Sebastian Bunk
Dominik Maurer
Jens FRITSCHE
Claudia Wagner
Leonie ALTEN
Franziska Hoffgaard
Mathias Ferber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immatics Biotechnologies GmbH
Original Assignee
Immatics Biotechnologies GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies GmbH filed Critical Immatics Biotechnologies GmbH
Priority to DE102016123893.7A priority Critical patent/DE102016123893A1/de
Priority to CR20190280A priority patent/CR20190280A/es
Priority to US15/833,778 priority patent/US11072645B2/en
Priority to KR1020227009598A priority patent/KR102639592B1/ko
Priority to KR1020197018153A priority patent/KR102379955B1/ko
Priority to MX2019006726A priority patent/MX2019006726A/es
Priority to JP2019529260A priority patent/JP7346294B2/ja
Priority to MA047359A priority patent/MA47359A/fr
Priority to PE2019001163A priority patent/PE20191150A1/es
Priority to CN201780075297.XA priority patent/CN110099923A/zh
Priority to EP17825761.4A priority patent/EP3551653B1/en
Priority to PCT/EP2017/081745 priority patent/WO2018104407A1/en
Priority to BR112019010803A priority patent/BR112019010803A2/pt
Priority to EP23207201.7A priority patent/EP4317432A3/en
Priority to NZ754222A priority patent/NZ754222A/en
Priority to CA3045230A priority patent/CA3045230A1/en
Priority to AU2017371260A priority patent/AU2017371260C1/en
Priority to TW106143062A priority patent/TWI710572B/zh
Publication of DE102016123893A1 publication Critical patent/DE102016123893A1/de
Priority to PH12019501243A priority patent/PH12019501243A1/en
Priority to IL267130A priority patent/IL267130A/en
Priority to CL2019001536A priority patent/CL2019001536A1/es
Priority to CONC2019/0006901A priority patent/CO2019006901A2/es
Priority to US17/354,555 priority patent/US12297252B2/en
Priority to JP2023010833A priority patent/JP2023052688A/ja
Priority to US19/024,104 priority patent/US20250163124A1/en
Priority to JP2025014650A priority patent/JP2025063330A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
DE102016123893.7A 2016-12-08 2016-12-08 T-Zellrezeptoren mit verbesserter Bindung Withdrawn DE102016123893A1 (de)

Priority Applications (26)

Application Number Priority Date Filing Date Title
DE102016123893.7A DE102016123893A1 (de) 2016-12-08 2016-12-08 T-Zellrezeptoren mit verbesserter Bindung
EP17825761.4A EP3551653B1 (en) 2016-12-08 2017-12-06 T cell receptors with improved pairing
EP23207201.7A EP4317432A3 (en) 2016-12-08 2017-12-06 T cell receptors with improved pairing
KR1020227009598A KR102639592B1 (ko) 2016-12-08 2017-12-06 짝짓기가 향상된 t 세포 수용체
KR1020197018153A KR102379955B1 (ko) 2016-12-08 2017-12-06 짝짓기가 향상된 t 세포 수용체
MX2019006726A MX2019006726A (es) 2016-12-08 2017-12-06 Receptores de celulas t con apareamiento mejorado.
JP2019529260A JP7346294B2 (ja) 2016-12-08 2017-12-06 対合が改善されたｔ細胞受容体ｔ細胞
MA047359A MA47359A (fr) 2016-12-08 2017-12-06 Récepteurs de lymphocytes t à appariement amélioré
PE2019001163A PE20191150A1 (es) 2016-12-08 2017-12-06 Receptores de celulas t con apareamiento mejorado
CN201780075297.XA CN110099923A (zh) 2016-12-08 2017-12-06 配对改善的t细胞受体
US15/833,778 US11072645B2 (en) 2016-12-08 2017-12-06 T cell receptors with improved pairing
PCT/EP2017/081745 WO2018104407A1 (en) 2016-12-08 2017-12-06 T cell receptors with improved pairing
CA3045230A CA3045230A1 (en) 2016-12-08 2017-12-06 T cell receptors with improved pairing
CR20190280A CR20190280A (es) 2016-12-08 2017-12-06 Receptores de células t con apareamiento mejorado
NZ754222A NZ754222A (en) 2016-12-08 2017-12-06 T cell receptors with improved pairing
BR112019010803A BR112019010803A2 (pt) 2016-12-08 2017-12-06 receptores de célula t com pareamento melhorado
AU2017371260A AU2017371260C1 (en) 2016-12-08 2017-12-06 T cell receptors with improved pairing
TW106143062A TWI710572B (zh) 2016-12-08 2017-12-08 改善配對的ｔ細胞受體
PH12019501243A PH12019501243A1 (en) 2016-12-08 2019-06-04 T cell receptors with improved pairing
CL2019001536A CL2019001536A1 (es) 2016-12-08 2019-06-05 Receptores de célula t con apareamiento mejorado.
IL267130A IL267130A (en) 2016-12-08 2019-06-05 T cell receptors with enhanced coupling
CONC2019/0006901A CO2019006901A2 (es) 2016-12-08 2019-06-27 Receptores de células t con apareamiento mejorado
US17/354,555 US12297252B2 (en) 2016-12-08 2021-06-22 T cell receptors with improved pairing
JP2023010833A JP2023052688A (ja) 2016-12-08 2023-01-27 対合が改善されたｔ細胞受容体ｔ細胞
US19/024,104 US20250163124A1 (en) 2016-12-08 2025-01-16 T cell receptors with improved pairing
JP2025014650A JP2025063330A (ja) 2016-12-08 2025-01-31 対合が改善されたｔ細胞受容体ｔ細胞

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102016123893.7A DE102016123893A1 (de) 2016-12-08 2016-12-08 T-Zellrezeptoren mit verbesserter Bindung

Publications (1)

Publication Number Publication Date
DE102016123893A1 true DE102016123893A1 (de) 2018-06-14

Family

ID=62201182

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102016123893.7A Withdrawn DE102016123893A1 (de) 2016-12-08 2016-12-08 T-Zellrezeptoren mit verbesserter Bindung

Country Status (14)

Country Link
US (2) US11072645B2 (enExample)
EP (1) EP3551653B1 (enExample)
JP (1) JP7346294B2 (enExample)
CN (1) CN110099923A (enExample)
AU (1) AU2017371260C1 (enExample)
BR (1) BR112019010803A2 (enExample)
CA (1) CA3045230A1 (enExample)
CR (1) CR20190280A (enExample)
DE (1) DE102016123893A1 (enExample)
MA (1) MA47359A (enExample)
MX (1) MX2019006726A (enExample)
PE (1) PE20191150A1 (enExample)
TW (1) TWI710572B (enExample)
WO (1) WO2018104407A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019086665A1 (en) 2017-11-06 2019-05-09 Immatics Biotechnologies Gmbh Novel engineered t cell receptors and immune therapy using the same
DE102017125888A1 (de) 2017-11-06 2019-05-23 Immatics Biotechnologies Gmbh Neue konstruierte T-Zell-Rezeptoren und deren Verwendung in Immuntherapie

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
RS62865B1 (sr) 2016-12-08 2022-02-28 Immatics Biotechnologies Gmbh Novi t-ćelijski receptori i imunoterapija u kojoj se koriste
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
DE102017106305A1 (de) 2017-03-23 2018-09-27 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten
DE102018108612A1 (de) 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
US20200297768A1 (en) 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
DE102019108125B4 (de) 2019-03-28 2022-02-03 Immatics US, Inc. Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung
PE20220164A1 (es) 2019-05-27 2022-01-28 Immatics Us Inc Vectores viricos y uso de los mismos en terapias celulares adoptivas
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
US20230132241A1 (en) 2020-01-15 2023-04-27 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
BR112022016909A2 (pt) 2020-02-24 2022-12-06 Immatics Us Inc Métodos para a expansão de células t para o tratamento de câncer e malignidades associadas
DE102020111571A1 (de) * 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
US20220056411A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
JP2024502034A (ja) 2020-12-31 2024-01-17 イマティクス ユーエス，アイエヌシー． Ｃｄ８ポリペプチド、組成物、及びそれらの使用方法
WO2022184805A1 (en) 2021-03-03 2022-09-09 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding sars-cov-2 antigenic peptides in complex with a major histocompatibility complex protein
BR112023022765A2 (pt) 2021-05-05 2024-01-02 Immatics Biotechnologies Gmbh Proteínas de ligação ao antígeno que ligam especificamente o prame
MX2024001179A (es) 2021-07-27 2024-02-27 Immatics Biotechnologies Gmbh Proteinas de union a antigenos que se unen especificamente a ct45.
US20230089392A1 (en) 2021-09-20 2023-03-23 Immatics US, Inc. Monocyte depletion of t cells populations for t-cell therapy
WO2023081461A1 (en) 2021-11-08 2023-05-11 Immatics US, Inc. Methods for generating cell spheroids
EP4448108A1 (en) 2021-11-08 2024-10-23 Immatics Biotechnologies GmbH Adoptive cell therapy combination treatment and compositions thereof
EP4198052A1 (en) 2021-12-15 2023-06-21 Eberhard Karls Universität Tübingen Medizinische Fakultät Peptides and antigen binding proteins for use in immunotherapy against fibrolamellar hepatocellular carcinoma (fl-hcc) and other cancers
EP4514829A1 (en) 2022-04-28 2025-03-05 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
JP2025515604A (ja) 2022-04-28 2025-05-20 イマティクス ユーエス，アイエヌシー． ドミナントネガティブＴＧＦβ受容体ポリペプチド、ＣＤ８ポリペプチド、細胞、組成物、およびその使用方法
US20240066127A1 (en) 2022-04-28 2024-02-29 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
EP4519418A1 (en) 2022-05-05 2025-03-12 Immatics US, Inc. Methods for improving t cell efficacy
WO2025021979A1 (en) 2023-07-27 2025-01-30 Immatics Biotechnologies Gmbh Novel t cell receptors targeting melanoma-associated antigen (mage) b2 and immune therapy using the same
WO2025021968A1 (en) 2023-07-27 2025-01-30 Immatics Biotechnologies Gmbh Antigen binding proteins against mageb2
WO2025096649A1 (en) 2023-11-01 2025-05-08 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof

Citations (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003100432A2 (de) 2002-05-29 2003-12-04 Immatics Biotechnologies Gmbh Verfahren zur identifizierung von immunreaktiven peptiden
WO2003102023A1 (de) 2002-05-29 2003-12-11 Immatics Biotechnologies Gmbh An mhc-moleküle bindende tumor-assoziierte peptide
WO2004085461A2 (de) 2003-03-24 2004-10-07 Immatics Biotechnologies Gmbh An mhc-moleküle bindende tumor-assoziierte peptide
WO2005076009A2 (en) 2004-01-28 2005-08-18 Immatics Biotechnologies Gmbh Method for identifying and quantifying of tumour-associated peptides
WO2005116051A2 (de) 2004-05-25 2005-12-08 Immatics Biotechnologies Gmbh An mhc-moleküle bindende tumor-assoziierte peptide
WO2006114307A1 (en) 2005-04-26 2006-11-02 Immatics Biotechnologies Gmbh T-cell epitopes from the oncofetal antigen-immature laminin receptor protein and medical uses thereof
WO2007028574A2 (en) 2005-09-05 2007-03-15 Immatics Biotechnologies Gmbh Tumor-associated peptides binding promiscuously to human leukocyte antigen (hla) class ii molecules
WO2007028573A1 (en) 2005-09-05 2007-03-15 Immatics Biotechnologies Gmbh Tumor-associated peptides binding to human leukocyte antigen (hla) class i or ii molecules and related anti-cancer vaccine
WO2009015843A1 (en) 2007-07-27 2009-02-05 Immatics Biotechnologies Gmbh Novel immunotherapy against neuronal and brain tumors
WO2009015842A2 (en) 2007-07-27 2009-02-05 Immatics Biotechnologies Gmbh Novel immunogenic epitopes for immunotherapy
WO2009015841A1 (en) 2007-07-27 2009-02-05 Immatics Biotechnologies Gmbh Composition of tumour-associated peptides and related anti-cancer vaccine
WO2009138236A1 (en) 2008-05-14 2009-11-19 Immatics Biotechnologies Gmbh Novel and powerful mhc-class ii petptides derived from survivin
WO2010037514A2 (en) 2008-10-01 2010-04-08 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors including neuronal and brain tumors
US20110070208A1 (en) * 2008-05-09 2011-03-24 Agency For Science, Technology And Research Hbv epitope reactive exogenous t cell receptor (tcr) and uses thereof
WO2011073215A2 (en) 2009-12-14 2011-06-23 Immatics Biotechnologies Gmbh Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
WO2011113819A2 (en) 2010-03-19 2011-09-22 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors including gastrointestinal and gastric cancer
WO2011113872A1 (en) 2010-03-19 2011-09-22 Immatics Biotechnologies Gmbh Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers
WO2011113882A1 (en) 2010-03-19 2011-09-22 Immatics Biotechnologies Gmbh Diagnosis and treatment of cancer based on avl9
WO2011128448A1 (en) 2010-04-16 2011-10-20 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed hla-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
WO2011151403A1 (en) 2010-06-02 2011-12-08 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumor associated antigens derived from cyclin d1
WO2012038463A2 (en) 2010-09-21 2012-03-29 Immatics Biotechnologies Gmbh Use of myeloid cell biomarkers for the diagnosis of cancer
WO2012069462A1 (en) 2010-11-24 2012-05-31 Immatics Biotechnologies Gmbh Biomarkers for predicting the efficacy of an immunotherapy against cancer
WO2012079878A2 (en) 2010-12-14 2012-06-21 Immatics Biotechnologies Gmbh Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
WO2014083173A1 (en) 2012-11-30 2014-06-05 Max-Delbrück-Centrum Für Molekulare Medizin (Mdc) Berlin-Buch Tumor specific t-cell receptors
WO2014153470A2 (en) 2013-03-21 2014-09-25 Sangamo Biosciences, Inc. Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases
WO2015018805A1 (en) 2013-08-05 2015-02-12 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors, such as lung cancer, including nsclc
WO2015063302A2 (en) 2013-11-04 2015-05-07 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
WO2015169945A2 (en) 2014-05-09 2015-11-12 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (aml)
WO2015193359A2 (en) 2014-06-20 2015-12-23 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll)
WO2016006397A1 (en) 2014-07-11 2016-01-14 Nec Corporation Communication system, control node, base station and method for congestion control on a backhaul link
WO2016065166A1 (en) 2014-10-22 2016-04-28 Intel Corporation Anti-moiré pattern diffuser for optical systems
WO2016064317A1 (en) 2014-10-24 2016-04-28 Telefonaktiebolaget L M Ericsson (Publ) Method and arrangement for csi-rs transmission
WO2016068727A1 (es) 2013-10-15 2016-05-06 Carlos Alberto Ibañez Vignolo Bicicleta híbrida motorizada 2x2
WO2016070146A1 (en) 2014-10-30 2016-05-06 Ecogensus, Llc Solid fuel composition formed from mixed solid waste
WO2016066706A1 (de) 2014-10-30 2016-05-06 Head Technology Gmbh Superelastische schlägersaite
WO2016065812A1 (zh) 2014-10-29 2016-05-06 小米科技有限责任公司 基于设定场景模式的智能设备控制方法和装置
WO2016073416A1 (en) 2014-11-03 2016-05-12 Hygeia Technology Inc. Phorbol ester compositions and methods for treating or reducing the duration of cytopenia
WO2016071343A1 (en) 2014-11-03 2016-05-12 Immures S.R.L. T cell receptors
WO2016073587A1 (en) 2014-11-04 2016-05-12 Spinal Stabilization Technologies Llc Percutaneous implantable nuclear prosthesis
WO2016079737A2 (en) 2014-11-17 2016-05-26 Mitrassist Medical Ltd. Heart valve prosthesis
WO2016078718A1 (en) 2014-11-20 2016-05-26 Abb Technology Ltd Electromagnetic brake system and method of controllong molten metal flow in a metal-making process
WO2016079059A1 (de) 2014-11-20 2016-05-26 Windmöller & Hölscher Kg Kontaktwalze
WO2016102272A1 (en) 2014-12-23 2016-06-30 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
WO2016107740A1 (en) 2014-12-30 2016-07-07 Immatics Biotechnologies Gmbh Method for the absolute quantification of naturally processed hla-restricted cancer peptides
WO2016146751A1 (en) 2015-03-17 2016-09-22 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
WO2016156202A1 (en) 2015-03-27 2016-10-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various tumors
WO2016156230A1 (en) 2015-03-31 2016-10-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (rcc) and other cancers
WO2016170139A1 (en) 2015-04-24 2016-10-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc and other cancers
WO2016177784A1 (en) 2015-05-06 2016-11-10 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2244744A1 (en) * 1996-02-01 1997-08-07 University Of Florida Lyst1 and lyst2 gene compositions and methods of use
EP1194542A1 (en) 1999-03-02 2002-04-10 Ludwig Institute For Cancer Research Cloning of cdna of mage's 5,8,9 and 11 and their uses in diagnosis of cancer
AU2273701A (en) 1999-12-13 2001-06-18 Epimmune, Inc. Hla class i a2 tumor associated antigen peptides and vaccine compositions
DE60133287T2 (de) 2000-07-31 2009-03-26 Green Peptide Co., Ltd., Kurume Tumorantigen
US20050063947A1 (en) 2002-03-27 2005-03-24 Patrick Hwu Method for treating cancer in humans
US7807392B1 (en) 2003-09-15 2010-10-05 Celera Corporation Lung disease targets and uses thereof
RU2007135030A (ru) 2005-02-24 2009-03-27 Симайнз, Инк. (Us) Композиции и способы классификации биологических образцов
WO2008053573A1 (fr) 2006-10-30 2008-05-08 National University Corporation Hokkaido University Remède pour néoplasme malin
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
US20110318380A1 (en) 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
GB0917094D0 (en) * 2009-09-29 2009-11-11 Ucl Biomedica Plc T-cell receptor
US20130011496A1 (en) 2009-11-25 2013-01-10 Ludwig Institute For Cancer Research Ltd. Cancer testis antigens as biomarkers in non-small cell lung cancer
US9114100B2 (en) 2010-05-17 2015-08-25 Duke University Methods of treatment using ex vivo expansion of cord blood T cells
CN101870725B (zh) 2010-06-29 2012-06-27 郑州大学 Mage-4抗肿瘤ctl表位肽及其应用
WO2013031882A1 (ja) 2011-08-31 2013-03-07 国立大学法人三重大学 がん治療用ワクチン製剤
WO2015172843A1 (en) 2014-05-16 2015-11-19 Biontech Diagnostics Gmbh Methods and kits for the diagnosis of cancer
JP6599450B2 (ja) 2014-10-02 2019-10-30 アメリカ合衆国 がん特異的突然変異に対し抗原特異性を有するｔ細胞を単離する方法
EP3067366A1 (en) 2015-03-13 2016-09-14 Max-Delbrück-Centrum Für Molekulare Medizin Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1
GB201510771D0 (en) 2015-06-19 2015-08-05 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer
GB201511191D0 (en) 2015-06-25 2015-08-12 Immatics Biotechnologies Gmbh T-cell epitopes for the immunotherapy of myeloma
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201511792D0 (en) 2015-07-06 2015-08-19 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers
GB201512369D0 (en) 2015-07-15 2015-08-19 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
GB201515321D0 (en) 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
GB201517538D0 (en) 2015-10-05 2015-11-18 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
EP3359565A1 (en) 2015-10-09 2018-08-15 Immatics Biotechnologies GmbH Anti-wt1/hla-specific antibodies
CN105219714A (zh) 2015-10-20 2016-01-06 上海隆耀生物科技有限公司 一种用于激活肺癌特异性免疫反应的试剂盒
GB201521746D0 (en) 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
GB201521894D0 (en) 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
GB201522667D0 (en) 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
DE102016123847B3 (de) 2016-12-08 2018-04-05 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
DE102016123859B3 (de) 2016-12-08 2018-03-01 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
AU2018298422B2 (en) 2017-07-04 2023-04-06 CureVac SE Novel nucleic acid molecules
US20210147550A1 (en) 2017-08-18 2021-05-20 Joshua Michael Francis Antigen-binding proteins targeting shared antigens
CN111315769A (zh) 2017-09-06 2020-06-19 加州理工学院 信号传导和抗原呈递双功能受体(sabr)
CN118256563A (zh) 2017-11-10 2024-06-28 北京卡替医疗技术有限公司 一种扩增免疫细胞的方法
WO2019133853A1 (en) 2017-12-28 2019-07-04 Gritstone Oncology, Inc. Antigen-binding proteins targeting shared antigens
FI3773689T3 (fi) 2018-04-11 2023-01-31 Antigeenisiä peptidejä syövän ehkäisyyn ja hoitoon
US20230002730A1 (en) 2018-05-18 2023-01-05 Children's National Medical Center Improved targeted t-cell therapy
AU2019275072A1 (en) 2018-05-23 2021-01-21 Seattle Project Corp. Shared antigens
EP3802614A1 (en) 2018-06-04 2021-04-14 Apo-T B.V. Methods and means for attracting immune effector cells to tumor cells
GB201819540D0 (en) 2018-11-30 2019-01-16 Adaptimmune Ltd T cell modification
CA3139011A1 (en) 2019-05-08 2020-11-12 Medigene Immunotherapies Gmbh Engineered t cells
EP3986938A4 (en) 2019-06-18 2023-06-28 Regeneron Pharmaceuticals, Inc. Mage-a4 t cell receptors and methods of use thereof

Patent Citations (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003100432A2 (de) 2002-05-29 2003-12-04 Immatics Biotechnologies Gmbh Verfahren zur identifizierung von immunreaktiven peptiden
WO2003102023A1 (de) 2002-05-29 2003-12-11 Immatics Biotechnologies Gmbh An mhc-moleküle bindende tumor-assoziierte peptide
WO2004085461A2 (de) 2003-03-24 2004-10-07 Immatics Biotechnologies Gmbh An mhc-moleküle bindende tumor-assoziierte peptide
WO2005076009A2 (en) 2004-01-28 2005-08-18 Immatics Biotechnologies Gmbh Method for identifying and quantifying of tumour-associated peptides
WO2005116051A2 (de) 2004-05-25 2005-12-08 Immatics Biotechnologies Gmbh An mhc-moleküle bindende tumor-assoziierte peptide
WO2006114307A1 (en) 2005-04-26 2006-11-02 Immatics Biotechnologies Gmbh T-cell epitopes from the oncofetal antigen-immature laminin receptor protein and medical uses thereof
WO2007028574A2 (en) 2005-09-05 2007-03-15 Immatics Biotechnologies Gmbh Tumor-associated peptides binding promiscuously to human leukocyte antigen (hla) class ii molecules
WO2007028573A1 (en) 2005-09-05 2007-03-15 Immatics Biotechnologies Gmbh Tumor-associated peptides binding to human leukocyte antigen (hla) class i or ii molecules and related anti-cancer vaccine
WO2009015843A1 (en) 2007-07-27 2009-02-05 Immatics Biotechnologies Gmbh Novel immunotherapy against neuronal and brain tumors
WO2009015842A2 (en) 2007-07-27 2009-02-05 Immatics Biotechnologies Gmbh Novel immunogenic epitopes for immunotherapy
WO2009015841A1 (en) 2007-07-27 2009-02-05 Immatics Biotechnologies Gmbh Composition of tumour-associated peptides and related anti-cancer vaccine
US20110070208A1 (en) * 2008-05-09 2011-03-24 Agency For Science, Technology And Research Hbv epitope reactive exogenous t cell receptor (tcr) and uses thereof
WO2009138236A1 (en) 2008-05-14 2009-11-19 Immatics Biotechnologies Gmbh Novel and powerful mhc-class ii petptides derived from survivin
WO2010037514A2 (en) 2008-10-01 2010-04-08 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors including neuronal and brain tumors
WO2011073215A2 (en) 2009-12-14 2011-06-23 Immatics Biotechnologies Gmbh Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
WO2011113819A2 (en) 2010-03-19 2011-09-22 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors including gastrointestinal and gastric cancer
WO2011113872A1 (en) 2010-03-19 2011-09-22 Immatics Biotechnologies Gmbh Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers
WO2011113882A1 (en) 2010-03-19 2011-09-22 Immatics Biotechnologies Gmbh Diagnosis and treatment of cancer based on avl9
WO2011128448A1 (en) 2010-04-16 2011-10-20 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed hla-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
WO2011151403A1 (en) 2010-06-02 2011-12-08 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumor associated antigens derived from cyclin d1
WO2012038463A2 (en) 2010-09-21 2012-03-29 Immatics Biotechnologies Gmbh Use of myeloid cell biomarkers for the diagnosis of cancer
WO2012069462A1 (en) 2010-11-24 2012-05-31 Immatics Biotechnologies Gmbh Biomarkers for predicting the efficacy of an immunotherapy against cancer
WO2012079878A2 (en) 2010-12-14 2012-06-21 Immatics Biotechnologies Gmbh Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
WO2014083173A1 (en) 2012-11-30 2014-06-05 Max-Delbrück-Centrum Für Molekulare Medizin (Mdc) Berlin-Buch Tumor specific t-cell receptors
WO2014153470A2 (en) 2013-03-21 2014-09-25 Sangamo Biosciences, Inc. Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases
WO2015018805A1 (en) 2013-08-05 2015-02-12 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors, such as lung cancer, including nsclc
WO2016068727A1 (es) 2013-10-15 2016-05-06 Carlos Alberto Ibañez Vignolo Bicicleta híbrida motorizada 2x2
WO2015063302A2 (en) 2013-11-04 2015-05-07 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
WO2015169945A2 (en) 2014-05-09 2015-11-12 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (aml)
WO2015193359A2 (en) 2014-06-20 2015-12-23 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll)
WO2016006397A1 (en) 2014-07-11 2016-01-14 Nec Corporation Communication system, control node, base station and method for congestion control on a backhaul link
WO2016065166A1 (en) 2014-10-22 2016-04-28 Intel Corporation Anti-moiré pattern diffuser for optical systems
WO2016064317A1 (en) 2014-10-24 2016-04-28 Telefonaktiebolaget L M Ericsson (Publ) Method and arrangement for csi-rs transmission
WO2016065812A1 (zh) 2014-10-29 2016-05-06 小米科技有限责任公司 基于设定场景模式的智能设备控制方法和装置
WO2016070146A1 (en) 2014-10-30 2016-05-06 Ecogensus, Llc Solid fuel composition formed from mixed solid waste
WO2016066706A1 (de) 2014-10-30 2016-05-06 Head Technology Gmbh Superelastische schlägersaite
WO2016071343A1 (en) 2014-11-03 2016-05-12 Immures S.R.L. T cell receptors
WO2016073416A1 (en) 2014-11-03 2016-05-12 Hygeia Technology Inc. Phorbol ester compositions and methods for treating or reducing the duration of cytopenia
WO2016073587A1 (en) 2014-11-04 2016-05-12 Spinal Stabilization Technologies Llc Percutaneous implantable nuclear prosthesis
WO2016079737A2 (en) 2014-11-17 2016-05-26 Mitrassist Medical Ltd. Heart valve prosthesis
WO2016078718A1 (en) 2014-11-20 2016-05-26 Abb Technology Ltd Electromagnetic brake system and method of controllong molten metal flow in a metal-making process
WO2016079059A1 (de) 2014-11-20 2016-05-26 Windmöller & Hölscher Kg Kontaktwalze
WO2016102272A1 (en) 2014-12-23 2016-06-30 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
WO2016107740A1 (en) 2014-12-30 2016-07-07 Immatics Biotechnologies Gmbh Method for the absolute quantification of naturally processed hla-restricted cancer peptides
WO2016146751A1 (en) 2015-03-17 2016-09-22 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
WO2016156202A1 (en) 2015-03-27 2016-10-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various tumors
WO2016156230A1 (en) 2015-03-31 2016-10-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (rcc) and other cancers
WO2016170139A1 (en) 2015-04-24 2016-10-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc and other cancers
WO2016177784A1 (en) 2015-05-06 2016-11-10 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers

Non-Patent Citations (33)

* Cited by examiner, † Cited by third party
Title
2. YANGBING, Z.; [u. a.]: High efficiency transfection of primary human and mouse T Lymphocytes using RNA electroporation. 2006. In: Mol. Ther., Vol. 13, S. 151-159. *
Bendle et al., 2009
Bendle GM et al. Preclinical development of T cell receptor gene therapy. Curr. Opin. Immunol. (2009). 21, 209-214
Chang et al [Chang HC et al. (1994) Proc Natl Acad Sci U S A 91(24): 11408-12]
Chen et al., 2005
Chen, JL et al (2005). Structural and kinetic basis for heightened immunogenicity of T cell vaccines. The Journal of Experimental Medicine, 201(8), 1243-1255
Cohen CJ et al. Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Res. 2006 Sep 1;66(17):8878-86
Cohen CJ et al. Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res. 2007 Apr 15;67(8):3898-903
Govers C et al. T cell receptor gene therapy: strategies for optimizing transgenic TCR pairing. Trends Mol Med. (2010) Feb;16(2):77-87
Huang X et al. Sleeping Beauty Transposon-mediated Engineering of Human Primary T Cells for Therapy of CD19+ Lymphoid Malignancies. Molecular Therapy (2008); 16 3, 580-589
Hughes RA et al. Gene synthesis: methods and applications. Methods Enzymol. (2011); 498: 277-309
Knies et al. An optimized single chain TCR scaffold relying on the assembly with the native CD3-complex prevents residual mispairing with endogenous TCRs in human T-cells. Oncotarget. 2016 Apr 19; 7(16): 21199-21221
Labrou et al (2010)
Labrou NE. Random mutagenesis methods for in vitro directed enzyme evolution. Curr Protein Pept Sci. (2010) Feb; 11(1):91 -100
Lefranc et al, 2001
Lefranc et al, 2001, Strong et al., 1999
Lefranc MP et al. The T cell receptor facts book. 2001
Løset GA et al., Phage Display Engineered T Cell Receptors as Tools for the Study of Tumor Peptide-MHC Interactions. Front Oncol (2014); 4: 378
Maeder ML & Gersbach CA. Genome-editing Technologies for Gene and Cell Therapy. Molecular Therapy (2016); 24 3, 430-446
O'Shea et al [O'Shea E, Lumb K, Kim P. (1993) Current Biology 3(10):658-667]
Pettersen EF et al (2004). UCSF Chimera--a visualization system for exploratory research and analysis. Journal of Computational Chemistry, 25(13), 1605-1612
Pogulis RJ, Pease LR. A retroviral vector that directs simultaneous expression of α and β T cell receptor genes. Hum Gene Ther. (1998) Oct 10;9(15): 2299-304
Spassov et al. (Spassov & Yan, 2013
Spassov VZ & Yan L (2013). pH-selective mutagenesis of protein-protein interfaces: in silico design of therapeutic antibodies with prolonged half-life. Proteins: Structure, Function, and Bioinformatics, 81(4), 704-714
Strong et al., 1999
Trehan A et al. REPLACR-mutagenesis, a one-step method for site-direc Scientific Reports (2016) 6, Article number: 19121
Trehan et al (2016)
Varriale S, et al. (2010) Mol Phylogenet Evol 57: 1238-44
Verhoeyen E et al. Lentiviral vector gene transfer into human T cells. Methods Mol Biol. 2009;506:97-114
Voss RH et al. Molecular design of the Calphabeta interface favors specific pairing of introduced TCRalphabeta in human T cells. J Immunol. 2008 Jan 1; 180(1):391-401. Walter et al. (2003) J Immunol., Nov 15;171(10):4974-8
Wälchli S et al. A Practical Approach to T-Cell Receptor Cloning and Expression. PLOS ONE (2011) 6(11): e27930
Zhong S et al. Retroviral Transduction of T-cell Receptors in Mouse T-cells J Vis Exp. (2010); (44): 2307
Zong et al (2010)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019086665A1 (en) 2017-11-06 2019-05-09 Immatics Biotechnologies Gmbh Novel engineered t cell receptors and immune therapy using the same
DE102017125888A1 (de) 2017-11-06 2019-05-23 Immatics Biotechnologies Gmbh Neue konstruierte T-Zell-Rezeptoren und deren Verwendung in Immuntherapie
EP4219543A1 (en) 2017-11-06 2023-08-02 Immatics Biotechnologies GmbH Novel engineered t cell receptors and immune therapy using the same

Also Published As

Publication number Publication date
MA47359A (fr) 2019-12-04
TW201827460A (zh) 2018-08-01
AU2017371260A1 (en) 2019-06-20
JP2020500525A (ja) 2020-01-16
EP3551653A1 (en) 2019-10-16
BR112019010803A2 (pt) 2019-10-01
WO2018104407A1 (en) 2018-06-14
US20180162922A1 (en) 2018-06-14
JP7346294B2 (ja) 2023-09-19
US11072645B2 (en) 2021-07-27
US12297252B2 (en) 2025-05-13
US20210380659A1 (en) 2021-12-09
PE20191150A1 (es) 2019-09-02
EP3551653B1 (en) 2023-11-01
AU2017371260C1 (en) 2020-11-19
MX2019006726A (es) 2019-09-04
CR20190280A (es) 2019-10-07
CN110099923A (zh) 2019-08-06
TWI710572B (zh) 2020-11-21
CA3045230A1 (en) 2018-06-14
AU2017371260B2 (en) 2020-07-23

Similar Documents

Publication Publication Date Title
DE102016123893A1 (de) T-Zellrezeptoren mit verbesserter Bindung
DE69522216T2 (de) Zielzellen-bindende chimäre Peptide
DE69229428T2 (de) Therapeutisch nützliche peptide und peptidfragmente
DE68923990T2 (de) Zellen mit ausgestattener Antikörperspezifität.
DE69332485T2 (de) Immunmodulierende peptide
DE102016115246C5 (de) Neue t-zellrezeptoren und deren verwendung in immuntherapie
DE60319745T2 (de) Modifizierte löslicher t-zellen-rezeptor
DE60203125T2 (de) Löslicher t zell rezeptor
DE69936927T2 (de) Polyspezifische bindemoleküle und deren verwendung
DE102019121007A1 (de) Antigenbindende Proteine, die spezifisch an MAGE-A binden
DE102016123859B3 (de) Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
EP1444268B1 (de) Bispezifisches anti-cd28 antikörper-molekül
DE69132925T2 (de) An stabile proteinkernstruktur gebundene proteinpolyliganden
DE69023900T4 (de) Gentechnologisch veränderte immunglobuline.
DE69837012T2 (de) Herstellung von Impfstoffen zur Vorbeugung von Pathogenen Zuständen einer HIV retroviralen Infektion
DE102017106305A1 (de) Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten
DE102017114737A1 (de) Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
CN105530959A (zh) 多聚化技术
DE60131413T2 (de) Verfahren zum auffinden von peptiden zur verwendung in der immuntherapie
DE69029858T2 (de) Behandlung von einer autoimmun-krankheit
US20250163124A1 (en) T cell receptors with improved pairing
DE3884440T2 (de) Methode und Mittel zur vorbeugenden Behandlung von Autoimmunkrankheiten.
WO1997010335A1 (de) Rekombinantes polypeptid basierend auf der primärsequenz der invarianten kette mit mindestens einer primärsequenz von einem spezifischen t-zellepitop oder eines proteinderivats und dieses rekombinante polypeptid kodierende nukleinsäuren
EP1308167A1 (de) Antigenpräsentierende Vesikel
DE69124518T2 (de) Herstellung monoklonaler Antikörper gegen menschliches Vbeta T-Zellrezeptorelement unter Verwendung rekombinanter DNA-Vektoren

Legal Events

Date Code Title Description
R012 Request for examination validly filed
R016 Response to examination communication
R082 Change of representative

Representative=s name: ZSP PATENTANWAELTE PARTG MBB, DE

Representative=s name: ZWICKER SCHNAPPAUF & PARTNER PATENTANWAELTE PA, DE

R082 Change of representative

Representative=s name: ZWICKER SCHNAPPAUF & PARTNER PATENTANWAELTE PA, DE

R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee